2025 Q3 -tulosraportti
31 päivää sitten38 min
Tarjoustasot
First North Denmark
Määrä
Osto
331
Myynti
Määrä
1 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 150 | - | - | ||
| 82 | - | - | ||
| 10 | - | - | ||
| 5 | - | - |
Ylin
15,35VWAP
Alin
14,75VaihtoMäärä
0 247
VWAP
Ylin
15,35Alin
14,75VaihtoMäärä
0 247
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 150 | 150 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 150 | 150 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 10.11. | |
| 2025 Q2 -tulosraportti | 21.8. | |
| 2025 Q1 -tulosraportti | 5.5. | |
| 2024 Q4 -tulosraportti | 21.3. | |
| 2024 Q3 -tulosraportti | 8.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·8 t sittenCHAT-GPT 1. Udgangspunkt: Where does ViroGates stand today? Markedsværdi: approx. 143 mio. Omsætning: approx. 5 mio. kr. Kapitaltilførsel: recently completed, which extends runway, but still not enough for full global commercialization without further kapitaltilførsel in a vækstscenarie. Produkt: suPARnostic® – which is primarily used for triage (emergency departments, sepsis risk assessment, emergency medicine). Unique selling point: A relatively inexpensive biomarker that can predict severe disease progression, which fits well with hospitals' desire for better resource allocation. Barrierer: Hospitals do not change protocols without heavy documentation, KOL-påvirkning, and time (typically 3–7 years for broad adoption). Your point that “it is quite easy to add yet another bio-markør” is technically entirely correct — but the difficulty lies in implementation in clinical practice, not the test itself. 2. How big can the market be? Danmark: ~25–30 mio. blood samples per year (gross). Of these, perhaps 4–6 mio. are relevant for emergency-/hospital flows, where suPAR is obvious. Europa: Estimate for emergency visits: +200 mio. annually. If suPAR became standard triage for just 1 % of relevant European blood samples, we are talking about: 2 mio. tests/year Pris per test (lab-level): 50–120 kr. (depending on volume and contract) => Revenue of 100–240 mio. kr. in Europe alone with only 1 % adoption. This merely shows how extremely elastic the potential is. 3. Realistic optimistic 1–5 year projection We assume three scenarios: Base, Optimistic, High-case (rare, but possible). 0–12 months (2025) Focus: kapitaldisciplin, focus markets (typically Germany, Spain, Nordics). Hospitals test protocols; suPAR included in several academic studies. Omsætning: 7–12 mio. kr. (growth 40–120 %) EBITDA: still negative, but smaller loss per year. Year 2 (2026) More hospitals transition from pilot to routine use. If 30–50 hospitals use the test continuously, it can yield: Omsætning: 20–35 mio. kr. Bruttomargin: 60–70 %. Markedsværdi: 250–450 mio. (if the market believes in the growth curve). Year 3 (2027) This is where it truly gets interesting. For diagnostics companies, there is an “S-curve moment” where adoption accelerates if the product becomes a clinical standard-of-care recommendation. If suPAR receives just one EU-EMS guideline-rekommandation or major RCT-results: Omsætning: 50–90 mio. kr. Markedsværdi: 500–900 mio. kr. Antal test/year: 0,5–1 mio. At this point, the market will start thinking: “Okay, ViroGates can become profitable within a short time.” Year 4–5 (2028–2029) – Optimistic scenario If adoption continues into Europe, and perhaps a couple of geographies outside (MENA, Asia, possibly later USA), we get the following potential: Omsætning: 150–300 mio. kr. EBITDA: 40–80 mio. Markedsværdi: 1,5–3,0 mia. kr. This does not require the “dream of global standard”, but merely solid pan-European adoption in emergency medicine. 4. High-case scenario (more aggressive, but possible) To illustrate theoretical upside: If suPAR becomes a standard-test in triage in 5–10 % of European emergency units: 10–25 mio. tests/year ViroGates-share 20–30 % of volume Pris: 30–90 kr/test => Omsætning: 200–700 mio. kr. => Markedsværdi: 2–5 mia. kr. This corresponds to a moderate success-case in the diagnostics industry, not a fantasy scenario. 5. What speaks against it? (The realistic risks) Hospitals slowly implement new biomarkers. Large diagnostics giants (Roche, Abbott, Siemens) can counteract adoption. Clinical guidelines are extremely difficult to change. The company may need another kapitaltilførsel before break-even. The USA-market requires FDA-approval and is expensive to penetrate. Early-stage diagnostics companies can stagnate if the KOL-network is not developed quickly enough. 6. Conclusion: What is a realistic optimistic projection? Year 1: Omsætning 7–12 mio. kr. | Markedsværdi ~200 mio. Year 2: Omsætning 20–35 mio. kr. | Markedsværdi 250–450 mio. Year 3: Omsætning 50–90 mio. kr. | Markedsværdi 500–900 mio. Year 4–5: Omsætning 150–300 mio. kr. | Markedsværdi 1,5–3 mia. kr. This does not require miracles — merely solid adoption in Europe and continuous clinical data.- ·18.11.Now, the newcomers must not get any new shares....
·19.11.I think it was absolutely the right thing to do. Last time they carried out a rights issue, it was a failure. Although it causes dilution, it's positive that the larger investors have enough confidence in the product to inject a small 20 million into the company. - ·14.10. · MuokattuI personally have no interest in selling at 13.58. I also see the offer from suPAR Remedy LLC as an expression that they see significant value in the company in the long term. I hold.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
31 päivää sitten38 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 t sittenCHAT-GPT 1. Udgangspunkt: Where does ViroGates stand today? Markedsværdi: approx. 143 mio. Omsætning: approx. 5 mio. kr. Kapitaltilførsel: recently completed, which extends runway, but still not enough for full global commercialization without further kapitaltilførsel in a vækstscenarie. Produkt: suPARnostic® – which is primarily used for triage (emergency departments, sepsis risk assessment, emergency medicine). Unique selling point: A relatively inexpensive biomarker that can predict severe disease progression, which fits well with hospitals' desire for better resource allocation. Barrierer: Hospitals do not change protocols without heavy documentation, KOL-påvirkning, and time (typically 3–7 years for broad adoption). Your point that “it is quite easy to add yet another bio-markør” is technically entirely correct — but the difficulty lies in implementation in clinical practice, not the test itself. 2. How big can the market be? Danmark: ~25–30 mio. blood samples per year (gross). Of these, perhaps 4–6 mio. are relevant for emergency-/hospital flows, where suPAR is obvious. Europa: Estimate for emergency visits: +200 mio. annually. If suPAR became standard triage for just 1 % of relevant European blood samples, we are talking about: 2 mio. tests/year Pris per test (lab-level): 50–120 kr. (depending on volume and contract) => Revenue of 100–240 mio. kr. in Europe alone with only 1 % adoption. This merely shows how extremely elastic the potential is. 3. Realistic optimistic 1–5 year projection We assume three scenarios: Base, Optimistic, High-case (rare, but possible). 0–12 months (2025) Focus: kapitaldisciplin, focus markets (typically Germany, Spain, Nordics). Hospitals test protocols; suPAR included in several academic studies. Omsætning: 7–12 mio. kr. (growth 40–120 %) EBITDA: still negative, but smaller loss per year. Year 2 (2026) More hospitals transition from pilot to routine use. If 30–50 hospitals use the test continuously, it can yield: Omsætning: 20–35 mio. kr. Bruttomargin: 60–70 %. Markedsværdi: 250–450 mio. (if the market believes in the growth curve). Year 3 (2027) This is where it truly gets interesting. For diagnostics companies, there is an “S-curve moment” where adoption accelerates if the product becomes a clinical standard-of-care recommendation. If suPAR receives just one EU-EMS guideline-rekommandation or major RCT-results: Omsætning: 50–90 mio. kr. Markedsværdi: 500–900 mio. kr. Antal test/year: 0,5–1 mio. At this point, the market will start thinking: “Okay, ViroGates can become profitable within a short time.” Year 4–5 (2028–2029) – Optimistic scenario If adoption continues into Europe, and perhaps a couple of geographies outside (MENA, Asia, possibly later USA), we get the following potential: Omsætning: 150–300 mio. kr. EBITDA: 40–80 mio. Markedsværdi: 1,5–3,0 mia. kr. This does not require the “dream of global standard”, but merely solid pan-European adoption in emergency medicine. 4. High-case scenario (more aggressive, but possible) To illustrate theoretical upside: If suPAR becomes a standard-test in triage in 5–10 % of European emergency units: 10–25 mio. tests/year ViroGates-share 20–30 % of volume Pris: 30–90 kr/test => Omsætning: 200–700 mio. kr. => Markedsværdi: 2–5 mia. kr. This corresponds to a moderate success-case in the diagnostics industry, not a fantasy scenario. 5. What speaks against it? (The realistic risks) Hospitals slowly implement new biomarkers. Large diagnostics giants (Roche, Abbott, Siemens) can counteract adoption. Clinical guidelines are extremely difficult to change. The company may need another kapitaltilførsel before break-even. The USA-market requires FDA-approval and is expensive to penetrate. Early-stage diagnostics companies can stagnate if the KOL-network is not developed quickly enough. 6. Conclusion: What is a realistic optimistic projection? Year 1: Omsætning 7–12 mio. kr. | Markedsværdi ~200 mio. Year 2: Omsætning 20–35 mio. kr. | Markedsværdi 250–450 mio. Year 3: Omsætning 50–90 mio. kr. | Markedsværdi 500–900 mio. Year 4–5: Omsætning 150–300 mio. kr. | Markedsværdi 1,5–3 mia. kr. This does not require miracles — merely solid adoption in Europe and continuous clinical data.
- ·18.11.Now, the newcomers must not get any new shares....·19.11.I think it was absolutely the right thing to do. Last time they carried out a rights issue, it was a failure. Although it causes dilution, it's positive that the larger investors have enough confidence in the product to inject a small 20 million into the company.
- ·14.10. · MuokattuI personally have no interest in selling at 13.58. I also see the offer from suPAR Remedy LLC as an expression that they see significant value in the company in the long term. I hold.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
331
Myynti
Määrä
1 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 150 | - | - | ||
| 82 | - | - | ||
| 10 | - | - | ||
| 5 | - | - |
Ylin
15,35VWAP
Alin
14,75VaihtoMäärä
0 247
VWAP
Ylin
15,35Alin
14,75VaihtoMäärä
0 247
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 150 | 150 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 150 | 150 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 10.11. | |
| 2025 Q2 -tulosraportti | 21.8. | |
| 2025 Q1 -tulosraportti | 5.5. | |
| 2024 Q4 -tulosraportti | 21.3. | |
| 2024 Q3 -tulosraportti | 8.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
31 päivää sitten38 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.3.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 10.11. | |
| 2025 Q2 -tulosraportti | 21.8. | |
| 2025 Q1 -tulosraportti | 5.5. | |
| 2024 Q4 -tulosraportti | 21.3. | |
| 2024 Q3 -tulosraportti | 8.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 t sittenCHAT-GPT 1. Udgangspunkt: Where does ViroGates stand today? Markedsværdi: approx. 143 mio. Omsætning: approx. 5 mio. kr. Kapitaltilførsel: recently completed, which extends runway, but still not enough for full global commercialization without further kapitaltilførsel in a vækstscenarie. Produkt: suPARnostic® – which is primarily used for triage (emergency departments, sepsis risk assessment, emergency medicine). Unique selling point: A relatively inexpensive biomarker that can predict severe disease progression, which fits well with hospitals' desire for better resource allocation. Barrierer: Hospitals do not change protocols without heavy documentation, KOL-påvirkning, and time (typically 3–7 years for broad adoption). Your point that “it is quite easy to add yet another bio-markør” is technically entirely correct — but the difficulty lies in implementation in clinical practice, not the test itself. 2. How big can the market be? Danmark: ~25–30 mio. blood samples per year (gross). Of these, perhaps 4–6 mio. are relevant for emergency-/hospital flows, where suPAR is obvious. Europa: Estimate for emergency visits: +200 mio. annually. If suPAR became standard triage for just 1 % of relevant European blood samples, we are talking about: 2 mio. tests/year Pris per test (lab-level): 50–120 kr. (depending on volume and contract) => Revenue of 100–240 mio. kr. in Europe alone with only 1 % adoption. This merely shows how extremely elastic the potential is. 3. Realistic optimistic 1–5 year projection We assume three scenarios: Base, Optimistic, High-case (rare, but possible). 0–12 months (2025) Focus: kapitaldisciplin, focus markets (typically Germany, Spain, Nordics). Hospitals test protocols; suPAR included in several academic studies. Omsætning: 7–12 mio. kr. (growth 40–120 %) EBITDA: still negative, but smaller loss per year. Year 2 (2026) More hospitals transition from pilot to routine use. If 30–50 hospitals use the test continuously, it can yield: Omsætning: 20–35 mio. kr. Bruttomargin: 60–70 %. Markedsværdi: 250–450 mio. (if the market believes in the growth curve). Year 3 (2027) This is where it truly gets interesting. For diagnostics companies, there is an “S-curve moment” where adoption accelerates if the product becomes a clinical standard-of-care recommendation. If suPAR receives just one EU-EMS guideline-rekommandation or major RCT-results: Omsætning: 50–90 mio. kr. Markedsværdi: 500–900 mio. kr. Antal test/year: 0,5–1 mio. At this point, the market will start thinking: “Okay, ViroGates can become profitable within a short time.” Year 4–5 (2028–2029) – Optimistic scenario If adoption continues into Europe, and perhaps a couple of geographies outside (MENA, Asia, possibly later USA), we get the following potential: Omsætning: 150–300 mio. kr. EBITDA: 40–80 mio. Markedsværdi: 1,5–3,0 mia. kr. This does not require the “dream of global standard”, but merely solid pan-European adoption in emergency medicine. 4. High-case scenario (more aggressive, but possible) To illustrate theoretical upside: If suPAR becomes a standard-test in triage in 5–10 % of European emergency units: 10–25 mio. tests/year ViroGates-share 20–30 % of volume Pris: 30–90 kr/test => Omsætning: 200–700 mio. kr. => Markedsværdi: 2–5 mia. kr. This corresponds to a moderate success-case in the diagnostics industry, not a fantasy scenario. 5. What speaks against it? (The realistic risks) Hospitals slowly implement new biomarkers. Large diagnostics giants (Roche, Abbott, Siemens) can counteract adoption. Clinical guidelines are extremely difficult to change. The company may need another kapitaltilførsel before break-even. The USA-market requires FDA-approval and is expensive to penetrate. Early-stage diagnostics companies can stagnate if the KOL-network is not developed quickly enough. 6. Conclusion: What is a realistic optimistic projection? Year 1: Omsætning 7–12 mio. kr. | Markedsværdi ~200 mio. Year 2: Omsætning 20–35 mio. kr. | Markedsværdi 250–450 mio. Year 3: Omsætning 50–90 mio. kr. | Markedsværdi 500–900 mio. Year 4–5: Omsætning 150–300 mio. kr. | Markedsværdi 1,5–3 mia. kr. This does not require miracles — merely solid adoption in Europe and continuous clinical data.
- ·18.11.Now, the newcomers must not get any new shares....·19.11.I think it was absolutely the right thing to do. Last time they carried out a rights issue, it was a failure. Although it causes dilution, it's positive that the larger investors have enough confidence in the product to inject a small 20 million into the company.
- ·14.10. · MuokattuI personally have no interest in selling at 13.58. I also see the offer from suPAR Remedy LLC as an expression that they see significant value in the company in the long term. I hold.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
331
Myynti
Määrä
1 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 150 | - | - | ||
| 82 | - | - | ||
| 10 | - | - | ||
| 5 | - | - |
Ylin
15,35VWAP
Alin
14,75VaihtoMäärä
0 247
VWAP
Ylin
15,35Alin
14,75VaihtoMäärä
0 247
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 150 | 150 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 150 | 150 | 0 | 0 |